Product NDC: | 0703-5233 |
Proprietary Name: | daunorubicin hydrochloride |
Non Proprietary Name: | daunorubicin hydrochloride |
Active Ingredient(s): | 5 mg/mL & nbsp; daunorubicin hydrochloride |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0703-5233 |
Labeler Name: | Teva Parenteral Medicines, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA065035 |
Marketing Category: | ANDA |
Start Marketing Date: | 20040401 |
Package NDC: | 0703-5233-93 |
Package Description: | 10 VIAL, SINGLE-DOSE in 1 TRAY (0703-5233-93) > 4 mL in 1 VIAL, SINGLE-DOSE (0703-5233-91) |
NDC Code | 0703-5233-93 |
Proprietary Name | daunorubicin hydrochloride |
Package Description | 10 VIAL, SINGLE-DOSE in 1 TRAY (0703-5233-93) > 4 mL in 1 VIAL, SINGLE-DOSE (0703-5233-91) |
Product NDC | 0703-5233 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | daunorubicin hydrochloride |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 20040401 |
Marketing Category Name | ANDA |
Labeler Name | Teva Parenteral Medicines, Inc. |
Substance Name | DAUNORUBICIN HYDROCHLORIDE |
Strength Number | 5 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Anthracycline Topoisomerase Inhibitor [EPC],Anthracyclines [Chemical/Ingredient],Topoisomerase Inhibitors [MoA] |